Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
11.30
+0.04 (0.36%)
At close: Jun 27, 2025, 4:00 PM
11.22
-0.08 (-0.71%)
After-hours: Jun 27, 2025, 7:44 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Verve Therapeutics stock ranges from a low of $11 to a high of $24. The average analyst price target of $14.57 forecasts a 28.94% increase in the stock price over the next year.
Price Target: $14.57 (+28.94%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 2 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy → Hold Downgrades $20 → $14 | Buy → Hold | Downgrades | $20 → $14 | +19.47% | Jun 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $14 | Strong Buy → Hold | Downgrades | $14 | +19.47% | Jun 18, 2025 |
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades $12 | Buy → Hold | Downgrades | $12 | +6.19% | Jun 18, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $28 → $11 | Strong Buy → Hold | Downgrades | $28 → $11 | -2.65% | Jun 18, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 17, 2025 |
Financial Forecast
Revenue This Year
41.30M
from 32.33M
Increased by 27.75%
Revenue Next Year
13.17M
from 41.30M
Decreased by -68.11%
EPS This Year
-2.49
from -2.35
EPS Next Year
-2.87
from -2.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.3M | 33.6M | 47.3M | ||
| Avg | 41.3M | 13.2M | 13.9M | ||
| Low | 20.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.8% | -18.7% | 258.7% | ||
| Avg | 27.7% | -68.1% | 5.7% | ||
| Low | -35.4% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.02 | -2.24 | -2.12 | ||
| Avg | -2.49 | -2.87 | -2.63 | ||
| Low | -2.92 | -3.73 | -3.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.